Interdisciplinary surgery for advanced gynecologic malignancies: Outcome and complication rate.

Authors

null

Jelena Boeckhoff

Clinic for Gynecology, Gynecological Oncology and Gynecological Endocrinology, University Hospital Marburg, Marburg, Germany

Jelena Boeckhoff , Luisa terGlane , Uwe A. G. Wagner , Rainer Hofmann , Axel Hegele

Organizations

Clinic for Gynecology, Gynecological Oncology and Gynecological Endocrinology, University Hospital Marburg, Marburg, Germany, Department of Urology, Philipps University Marburg, Marburg, Germany, Department of Urology, University Hospital Marburg, Marburg, Germany, Department of Urology and Pediatric Urology, University of Marburg, Marburg, Germany

Research Funding

Other

Background: Advanced gynecologic malignancies are known to have a poor prognosis. Due to local invasion in adjacent organs, finding the most suitable therapeutic option is often difficult. This study aims to assess the outcome of interdisciplinary surgery for locally advanced gynecologic malignancies focusing on women treated by pelvic exenteration (PE). Methods: All women that were treated with PE at the University Hospital Marburg between 04/2011 and 06/2016, were enrolled in this retrospective study. A data sheet was prepared assessing e.g. demographic informations, tumor type and previous therapies. Furthermore, complication rate (Clavien Dindo, follow-up and outcome were evaluated. Results: From the 57 women identified, the indications for PE were malignancies of the cervix (47.2%), vagina (15.1%), vulva (13.2%), endometrium (11.3%), ovaries (5.7%) and undifferentiated (uterus) (1.9%). 51.9% were treated for recurrent cancer. 26% received no treatment prior to PE, 16%, 38%, 20% received 1, 2 or 3 previous treatments respectively (chemotherapy, radiation, surgery). 54.7% of the patients underwent anterior, 37.8% total and 7.5% posterior PE. Urinary diversion was predominantly ileum conduit (76%). Major complications (Clavien Dindo > 2) were observed for 40.4%, 19.2% had no complications. No correlation with clinical parameters (e.g. BMI, age, time of surgery), previous therapy or urinary diversion could be shown. Renal function improved significantly postoperatively (p < 0.05). Mean hospital stay was 25 d. Median overall survival (OS) was 15.2 months. It was not influenced by the entity of the tumor. Two years survival rate (SR) was 38.2%; 3 years SR 27.3%. After 47 months median follow-up time, 23.7% of the treated women were still alive. Conclusions: PE remains to be a meaningful treatment option for women with invasive gynecologic malignancies also after multiple previous therapies, showing acceptable complication rates and satisfactory OS in regard to the extensive nature of the malignancies and the procedure.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Gynecologic Cancer: Publication Only

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Citation

J Clin Oncol 37, 2019 (suppl; abstr e17002)

DOI

10.1200/JCO.2019.37.15_suppl.e17002

Abstract #

e17002

Abstract Disclosures

Similar Abstracts

First Author: Lakhvir Kaur

First Author: Emily Claire MacArthur

First Author: Sadahisa Ogasawara

Abstract

2023 ASCO Annual Meeting

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.

First Author: Mark Charles Korpics